About Maibo Pharmaceutical
Maibo Pharmaceutical is a company based in Taizhou (China) founded in 2018.. The company has 315 employees as of December 31, 2024. Maibo Pharmaceutical operates in a competitive market with competitors including Moderna, Horizon Therapeutics, Forge Biologics, argenx and Annexon, among others.
- Headquarter Taizhou, China
- Employees 315 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
- Legal Name Mabpharm Limited
-
Annual Revenue
$36.05 M (USD)190.7as on Dec 31, 2024
-
Net Profit
$-17.86 M (USD)40.03as on Dec 31, 2024
-
EBITDA
$-8.15 M (USD)59.36as on Dec 31, 2024
-
Latest Funding Round
-
Investors
-
Employee Count
315
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Maibo Pharmaceutical
Maibo Pharmaceutical is a publicly listed company on the HKEX with ticker symbol 2181 in Hong Kong, operating in the Commercial services sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Funding Insights of Maibo Pharmaceutical
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investments & Acquisitions by Maibo Pharmaceutical
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Maibo Pharmaceutical
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Maibo Pharmaceutical Comparisons
Competitors of Maibo Pharmaceutical
Maibo Pharmaceutical operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Horizon Therapeutics, Forge Biologics, argenx and Annexon, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| domain | founded_year | HQ Location |
Developer of drugs for treating rare and autoimmune diseases
|
|
| domain | founded_year | HQ Location |
Gene therapies for rare diseases are developed to treat patients.
|
|
| domain | founded_year | HQ Location |
Antibody-based drugs are developed for autoimmune diseases and cancer treatment.
|
|
| domain | founded_year | HQ Location |
Developer of antibodies to treat complement-mediated neurodegenerative diseases
|
|
| domain | founded_year | HQ Location |
Therapeutics for autoimmune diseases are developed by the company.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Maibo Pharmaceutical
Frequently Asked Questions about Maibo Pharmaceutical
When was Maibo Pharmaceutical founded?
Maibo Pharmaceutical was founded in 2018.
Where is Maibo Pharmaceutical located?
Maibo Pharmaceutical is headquartered in Taizhou, China. It is registered at Taizhou, Jiangsu, China.
Who is the current CEO of Maibo Pharmaceutical?
Weizhu Qian is the current CEO of Maibo Pharmaceutical.
How many employees does Maibo Pharmaceutical have?
As of Dec 31, 2024, the latest employee count at Maibo Pharmaceutical is 315.
What is the annual revenue of Maibo Pharmaceutical?
Annual revenue of Maibo Pharmaceutical is $36.05M as on Dec 31, 2024.
What does Maibo Pharmaceutical do?
Maibo Pharmaceutical was founded in 2018 and is based in Taizhou, China. Operations focus on the development of biologic drugs within the pharmaceutical sector, targeting cancer and autoimmune conditions. The product pipeline features CMAB007 (Omuzumab), a humanized monoclonal antibody for asthma treatment; CMAB009, intended for colorectal cancer; and CMAB008 (Infliximab), used for autoimmune diseases. Leadership is provided by CEO Weizhu Qian.
Who are the top competitors of Maibo Pharmaceutical?
Maibo Pharmaceutical's top competitors include Moderna, argenx and Forge Biologics.
Is Maibo Pharmaceutical publicly traded?
Yes, Maibo Pharmaceutical is publicly traded on HKEX under the ticker symbol 2181.
What is Maibo Pharmaceutical's ticker symbol?
The ticker symbol of Maibo Pharmaceutical is 2181 on HKEX.